BioMed Realty Trust Appoints Former Amylin President And Chief Executive Officer To Its Board Of Directors

   BioMed Realty Trust Appoints Former Amylin President And Chief Executive
                      Officer To Its Board Of Directors

PR Newswire

SAN DIEGO, Jan. 4, 2013

SAN DIEGO, Jan. 4, 2013 /PRNewswire/ -- BioMed Realty Trust, Inc. (NYSE: BMR)
today announced the appointment of Daniel M. Bradbury to its board of
directors, increasing the board to eight members.

"We are pleased to welcome Dan to our board," said Alan D. Gold, Chairman and
Chief Executive Officer of BioMed Realty. "Dan brings his extensive knowledge
of the life science industry, as well as proven experience as a successful and
dynamic leader, which we believe will contribute significantly to the
continued sound execution of our business model. His deep understanding of
our tenants' needs will enable us to continue to provide leading-edge life
science companies with the real estate necessary to advance their
groundbreaking innovation and discoveries. Dan is joining a strong board
group, which collectively possesses the breadth of skills in life science,
real estate, finance and corporate governance to provide sound advice and
guidance to BioMed Realty as we fulfill the unique needs of life science
organizations and create value for our stockholders."

Mr. Bradbury is the Managing Member of BioBrit, LLC, a life sciences
consulting and investment firm. He served as Chief Executive Officer of
Amylin Pharmaceuticals, Inc., from March 2007 until its acquisition by
Bristol-Myers Squibb Company in August 2012. Mr. Bradbury served as Amylin's
President from June 2006 until March 2007, as Chief Operating Officer from
June 2003 until June 2006, as Executive Vice President from June 2000 until
June 2003, and other positions in corporate development and marketing from
1994 until 2000. In addition, Mr. Bradbury was a member of the board of
directors of Amylin from June 2006 until August 2012. Prior to joining Amylin,
Mr. Bradbury spent ten years at SmithKline Beecham Pharmaceuticals, holding a
number of sales and marketing positions.

Mr. Bradbury is currently a member of the boards of directors of Illumina,
Inc., Geron Corporation, Corcept Therapeutics Inc. and Castle Biosciences,
Inc. and the board of trustees for the Keck Graduate Institute of the
Claremont Colleges. Mr. Bradbury also serves on the Advisory Council of the
University of California San Diego's Rady School of Management, the RAND
Health Board of Advisors, and the University of Miami's Innovation Corporate
Advisory Council. He received a Bachelor of Pharmacy from Nottingham
University and a Diploma in Management Studies from Harrow and Ealing Colleges
of Higher Education in the United Kingdom.

About BioMed Realty Trust

BioMed Realty delivers optimal real estate solutions for biotechnology and
pharmaceutical companies, scientific research institutions, government
agencies and other entities involved in the life science industry. BioMed
Realty owns or has interests in properties comprising approximately 13.1
million rentable square feet. The company's properties are located
predominantly in the major U.S. life science markets of Boston, San Francisco,
San Diego, Maryland, New York/New Jersey, Pennsylvania and Seattle, which have
well-established reputations as centers for scientific research. Additional
information is available at

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 based on current
expectations, forecasts and assumptions that involve risks and uncertainties
that could cause actual outcomes and results to differ materially. These risks
and uncertainties include, without limitation: general risks affecting the
real estate industry (including, without limitation, the inability to enter
into or renew leases, dependence on tenants' financial condition, and
competition from other developers, owners and operators of real estate);
adverse economic or real estate developments in the life science industry or
the company's target markets; risks associated with the availability and terms
of financing, the use of debt to fund acquisitions, developments and other
investments, and the ability to refinance indebtedness as it comes due;
failure to maintain the company's investment grade credit ratings with the
ratings agencies; failure to manage effectively the company's growth and
expansion into new markets, or to complete or integrate acquisitions and
developments successfully; reductions in asset valuations and related
impairment charges; risks and uncertainties affecting property development and
construction; risks associated with downturns in foreign, domestic and local
economies, changes in interest rates and foreign currency exchange rates, and
volatility in the securities markets; ownership of properties outside of the
United States that subject the company to different and potentially greater
risks than those associated with the company's domestic operations; risks
associated with the company's investments in loans, including borrower
defaults and potential principal losses; potential liability for uninsured
losses and environmental contamination; risks associated with the company's
potential failure to qualify as a REIT under the Internal Revenue Code of
1986, as amended, and possible adverse changes in tax and environmental laws;
and risks associated with the company's dependence on key personnel whose
continued service is not guaranteed. For a further list and description of
such risks and uncertainties, see the reports filed by the company with the
Securities and Exchange Commission, including the company's most recent annual
report on Form 10-K and quarterly reports on Form 10-Q. The company disclaims
any intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or

SOURCE BioMed Realty Trust, Inc.

Contact: Rick Howe, Senior Director, Corporate Communications, +1-858-207-5859
Press spacebar to pause and continue. Press esc to stop.